WO2005109991A2 - Anti-theileriosis vaccine - Google Patents
Anti-theileriosis vaccine Download PDFInfo
- Publication number
- WO2005109991A2 WO2005109991A2 PCT/IN2005/000154 IN2005000154W WO2005109991A2 WO 2005109991 A2 WO2005109991 A2 WO 2005109991A2 IN 2005000154 W IN2005000154 W IN 2005000154W WO 2005109991 A2 WO2005109991 A2 WO 2005109991A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- vaccine
- growth medium
- per
- infected
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 52
- 208000001117 Theileriasis Diseases 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 claims abstract description 61
- 241000283690 Bos taurus Species 0.000 claims abstract description 39
- 244000309466 calf Species 0.000 claims abstract description 31
- 239000001963 growth medium Substances 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 28
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 22
- 210000001563 schizont Anatomy 0.000 claims abstract description 18
- 239000002577 cryoprotective agent Substances 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000002609 medium Substances 0.000 claims abstract description 10
- 238000012360 testing method Methods 0.000 claims abstract description 8
- 230000036039 immunity Effects 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 7
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 6
- 230000004044 response Effects 0.000 claims abstract description 6
- 230000002489 hematologic effect Effects 0.000 claims abstract description 5
- 238000010790 dilution Methods 0.000 claims abstract description 4
- 239000012895 dilution Substances 0.000 claims abstract description 4
- 230000000670 limiting effect Effects 0.000 claims abstract description 4
- 239000000725 suspension Substances 0.000 claims abstract description 4
- 210000004748 cultured cell Anatomy 0.000 claims abstract description 3
- 230000000405 serological effect Effects 0.000 claims abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 28
- 241000238876 Acari Species 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 7
- 239000012888 bovine serum Substances 0.000 claims description 6
- 230000007918 pathogenicity Effects 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 238000005138 cryopreservation Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 239000006285 cell suspension Substances 0.000 claims description 3
- 238000011109 contamination Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 229940056360 penicillin g Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 238000010561 standard procedure Methods 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims description 2
- 229940049018 mycostatin Drugs 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000003046 sporozoite Anatomy 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 241000147033 Trentepohlia annulata Species 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 241000223778 Theileria annulata Species 0.000 abstract description 11
- 238000012258 culturing Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 10
- 238000002649 immunization Methods 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000001524 infective effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000223777 Theileria Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229950008349 buparvaquone Drugs 0.000 description 2
- KLLIVCPQDTYMLC-HDJSIYSDSA-N chembl292009 Chemical compound C1C[C@@H](C(C)(C)C)CC[C@@H]1CC1=C(O)C(=O)C2=CC=CC=C2C1=O KLLIVCPQDTYMLC-HDJSIYSDSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000012909 foetal bovine serum Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 241000276457 Gadidae Species 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241001586444 Trilophidia annulata Species 0.000 description 1
- 238000011166 aliquoting Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- XNYZHCFCZNMTFY-UHFFFAOYSA-N diminazene Chemical compound C1=CC(C(=N)N)=CC=C1N\N=N\C1=CC=C(C(N)=N)C=C1 XNYZHCFCZNMTFY-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000001505 hemoglobinuria Diseases 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- SCEVFJUWLLRELN-UHFFFAOYSA-N imidocarb Chemical compound C=1C=CC(C=2NCCN=2)=CC=1NC(=O)NC(C=1)=CC=CC=1C1=NCCN1 SCEVFJUWLLRELN-UHFFFAOYSA-N 0.000 description 1
- 229960004683 imidocarb Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001759 immunoprophylactic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- RQIPBIVCBNQPDN-UHFFFAOYSA-N methylsulfinylmethane;propane-1,2,3-triol Chemical compound CS(C)=O.OCC(O)CO RQIPBIVCBNQPDN-UHFFFAOYSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 230000022676 rumination Effects 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000001064 tick infestation Diseases 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A61K39/018—Babesia antigens, e.g. Theileria antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
Definitions
- This invention relates to an antMhe ⁇ eriosis vaccine and the process of preparing the same.
- This vaccine is safe for all exotic breeds, their cross-breds at all age groups of cattle even including neo born calves and pregnant cows as well as 5 indigenous calves and is able to protect vaccinated animals from bovine tropical theiieriosis.
- the drawback of the above vaccine is that it contains only 0.1 to 3 million ceils as compared to present invention which contains 5 mfliion cells.
- cryoprotectant used is glycerine at -60°C
- cryoprotectant used in the present invention Is dimethyl sulphoxide (DMSO) and i o the material is cryopreserved in liquid nitrogen at - 79° C.
- DMSO dimethyl sulphoxide
- the passage at which present vaccine has been prepared is 200 and it is a cloned culture developed from a single cell in comparison to the culture used at 6-12 passages in the said vaccine of patent no, DE2914813.
- Still another object of the present invention Is to propose an antMheileriosis vaccine and a process of preparing the same for immunization of cattle against bovine tropical theiieriosis, which has no side reactions and can be safely used even In a few days old calves as well as in pregnant and high yielding cattle i o without any adverse effects.
- a process for preparation of antMheileriosis vaccine comprising isolation of
- the infected adult Hyabmma ticks are pre-fed on a caff for 72 hours and collected in a sterilized glass tube.
- the ticks are thoroughly washed with water and 1% Cetavlon solution followed by normal saline and RPMI-1640 and the
- GUTS Ground-up Tick Supemate 15 henceforth referred to as Ground-up Tick Supemate (GUTS) containing sporozoites of T. annulata is aliquoted depending upon the number of Infected ticks to be taken as infective dose.
- the GUTS Is used for initiating infection or for challenge of vaccinated animals either fresh or stored in liquid nitrogen by adding glycerol dimethylsulphoxide (DMSO) as cryoprotectant until used as a Stabllate.
- DMSO glycerol dimethylsulphoxide
- the twice and thrice weekly passaged cultures are propagated upto 100 passages and cryopreserved at different passages so as to cryopreserve the stock at all levels. Thereafter, the cloned cultures were developed and passaged up to 200 passages and cryopreserved at different passages.
- the static cultures are processed up to one year and cultures are cryopreserved at different time
- Plating efficiency of the cultures was tested and cloned populations of T. annulata schizont infected cells as suspension cultures were developed from 25 single cells by using limiting dilution technique, wherein, culture at a particular passage Is so diluted as to obtain a cell population of 1x10 3 cells per ml. Cultures already passaged up to 90-100 passages either twice-weekly or thrice-weekly were used for this purpose. Such a diluted culture is then poured into cupark plates and then observed under microscope. Those wells which contained single
- the growth medium used is RPMI-1640 supplemented initially with foetal bovine serum and later on substituted by neonatal bovine serum or normal bovine serum taken in quantity of 10-20% by volume.
- antibiotics in the form of benzyl penicillin sodium @100 i.u. per ml, streptomycin sulphate @100 ⁇ g per ml 20 and mycostatin @ 10 i.u. per ml were added.
- 200m M of L-glutamine is also added. All the contents are pre-sterilised by filtration and made free from any micro-organism contamination by standard procedure.
- Cells from all flasks are pooled and their cell concentration adjusted to 10 10 e viable cells per ml.
- the total volume is measured and mixed with equal quantity of growth medium containing 20% dimethylsulphoxide (DMSO) so as to make the final concentration of cods at 5 x 10 8 viable cells per ml in growth medium containing 10% DMSO.
- DMSO dimethylsulphoxide
- the cell suspension is aliquoted in on ⁇ -ml pre-labelled sterile cryo-tubes and Immediately transferred to gas phase of liquid nitrogen container. The vials can be transferred to liquid phase of liquid nitrogen container next morning for Indefinite storage till use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AP2006003856A AP2709A (en) | 2004-05-14 | 2005-05-12 | An anti-theileriosis vaccine |
| IL179254A IL179254A (en) | 2004-05-14 | 2006-11-14 | Anti-theileriosis vaccine |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN880DE2004 | 2004-05-14 | ||
| IN880/DEL/2004 | 2004-05-14 | ||
| IN2103/DEL/2004 | 2004-10-26 | ||
| IN2103DE2004 | 2004-10-26 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| WO2005109991A2 true WO2005109991A2 (en) | 2005-11-24 |
| WO2005109991A3 WO2005109991A3 (en) | 2006-03-30 |
| WO2005109991B1 WO2005109991B1 (en) | 2006-04-27 |
| WO2005109991A8 WO2005109991A8 (en) | 2006-08-24 |
Family
ID=35394566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IN2005/000154 WO2005109991A2 (en) | 2004-05-14 | 2005-05-12 | Anti-theileriosis vaccine |
Country Status (5)
| Country | Link |
|---|---|
| AP (1) | AP2709A (ru) |
| IL (1) | IL179254A (ru) |
| MA (1) | MA28656B1 (ru) |
| RU (1) | RU2404800C2 (ru) |
| WO (1) | WO2005109991A2 (ru) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023072178A1 (en) * | 2021-10-27 | 2023-05-04 | Porton Advanced Solutions Ltd. | Methods for developing a cell line for producing virus in suspension cell culture |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2914813A1 (de) * | 1979-04-11 | 1980-12-04 | Inst Experimentalnoi Veterinar | Lebende kulturvakzine gegen theileriosis beim rindvieh und verfahren zu deren herstellung |
-
2005
- 2005-05-12 WO PCT/IN2005/000154 patent/WO2005109991A2/en active Application Filing
- 2005-05-12 RU RU2006144451/15A patent/RU2404800C2/ru not_active IP Right Cessation
- 2005-05-12 AP AP2006003856A patent/AP2709A/xx active
-
2006
- 2006-11-14 IL IL179254A patent/IL179254A/en active IP Right Grant
- 2006-12-08 MA MA29521A patent/MA28656B1/fr unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2914813A1 (de) * | 1979-04-11 | 1980-12-04 | Inst Experimentalnoi Veterinar | Lebende kulturvakzine gegen theileriosis beim rindvieh und verfahren zu deren herstellung |
Non-Patent Citations (2)
| Title |
|---|
| DATABASE MEDLINE [Online] PRESTON P.M. ET AL: 'Macrophage-mediated cytostasis and lymphocyte cytotoxicity in cattle immunized with Theileria annulata sporozoites or macroschizont-infected cell lines' Database accession no. 3146048 & PARASITE IMMUNOLOGY vol. 10, no. 6, 1988, pages 631 - 347 * |
| DATABASE MEDLINE [Online] WATHANGA J.M. ET AL: 'Cryopreservation of Theileria-infected lymphoblastoid cells with functional assessment of viability' Database accession no. 3810856 & TROPICAL ANIMAL HEALTH AND PRODUCTION vol. 18, no. 4, pages 191 - 197 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023072178A1 (en) * | 2021-10-27 | 2023-05-04 | Porton Advanced Solutions Ltd. | Methods for developing a cell line for producing virus in suspension cell culture |
Also Published As
| Publication number | Publication date |
|---|---|
| MA28656B1 (fr) | 2007-06-01 |
| IL179254A0 (en) | 2007-03-08 |
| WO2005109991A3 (en) | 2006-03-30 |
| IL179254A (en) | 2011-12-29 |
| RU2006144451A (ru) | 2008-06-20 |
| AP2709A (en) | 2013-07-30 |
| AP2006003856A0 (en) | 2006-12-31 |
| WO2005109991A8 (en) | 2006-08-24 |
| RU2404800C2 (ru) | 2010-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pipano | Schizonts and tick stages in immunization against Theileria annulata infection | |
| US7462359B2 (en) | Neospora vaccines | |
| NO159782B (no) | Anordning ved fjaersystem, foerst og fremst paa kjoeretoeyer. | |
| Pipano et al. | Immunization of cattle against Theileria annulata using killed schizont vaccine | |
| Oberem et al. | The production of heartwater vaccine | |
| Fish et al. | Vaccination of cattle against B. bovis infection with live attenuated parasites and non-viable immunogens | |
| RU2403063C1 (ru) | Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота | |
| RU2465313C2 (ru) | Вакцина для профилактики кокцидиоза (эймериоза) кур | |
| IE46498B1 (en) | New vaccine | |
| Pipano et al. | Frozen Anaplasma centrale vaccine against anaplasmosis in cattle | |
| EP0100710B1 (en) | Vaccine for the immunization of animals and men against toxoplasma gondii | |
| Yoshida et al. | Establishment of an attenuated ML-17 strain of Japanese encephalitis virus. | |
| WO2005109991A2 (en) | Anti-theileriosis vaccine | |
| Palya | Manual for the production of Marek's disease, Gumboro disease and inactivated Newcastle disease vaccines | |
| KR101210082B1 (ko) | 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법 | |
| EP0687471A1 (en) | Production of an efficacious toxoplasma gondii bradyzoite vaccine in tissue culture | |
| IQBAL et al. | Immune response of rabbits to hemorrhagic septicemia vaccine formulations adjuvanted with montanide ISA-206, paraffin oil and alum | |
| RU2425148C2 (ru) | Штамм brucella abortus уф-1 для приготовления биологических препаратов для диагностики и специфической профилактики бруцеллеза сельскохозяйственных животных | |
| RU2589819C1 (ru) | ВАКЦИНА ПРОТИВ ИНФЕКЦИОННОГО КЕРАТОКОНЪЮНКТИВИТА КРУПНОГО РОГАТОГО СКОТА НА ОСНОВЕ АНТИГЕНОВ БАКТЕРИЙ Moraxella bovis И Moraxella bovoculi | |
| US3704203A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| Pipano | Vaccination of cattle against Theileria annulata using culture-derived schizonts | |
| Pipana | Virulence and immunogenicity of cultured Theileria annulata schizonts | |
| Alvarez-Martinez et al. | Development of a live attenuated vaccine for the control of bovine babesiosis in Mexico | |
| KR20040039938A (ko) | 어류의 스쿠티카충에 대한 불활화 백신 | |
| NO119491B (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| B | Later publication of amended claims |
Effective date: 20051214 |
|
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 179254 Country of ref document: IL |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006144451 Country of ref document: RU |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |